Immatics N.V.

IMTX

$10.99

Name : Immatics N.V.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,473,050,880.00

EPSttm : -1.89

Immatics N.V.

$10.99

1.06%

$0.115

IMTX — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.79

Margin Of Safety %

Put/Call OI Ratio

0.38

EPS Next Q Diff

-0.12

EPS Last/This Y

0.12

EPS This/Next Y

-0.02

Price

10.85

Target Price

18.69

Analyst Recom

Performance Q

18.54

Upside

-317.7%

Beta

1.33

Ticker: IMTX

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-17	IMTX	9.85	2.78	0.00	1381
2026-03-18	IMTX	9.72	2.71	999.99	1391
2026-03-20	IMTX	9.46	2.69	33.33	1407
2026-03-25	IMTX	9.72	0.82	0.10	667
2026-03-26	IMTX	9.76	0.82	0.10	667
2026-03-27	IMTX	9.38	0.67	11.00	776
2026-03-30	IMTX	9.31	0.67	11.00	776
2026-03-31	IMTX	9.82	0.69	0.00	787
2026-04-01	IMTX	10.02	0.67	0.00	795
2026-04-06	IMTX	10.3	0.63	0.01	826
2026-04-07	IMTX	10.27	0.49	0.00	977
2026-04-08	IMTX	10.57	0.42	0.00	1089
2026-04-09	IMTX	10.65	0.40	0.00	1130
2026-04-10	IMTX	10.43	0.40	0.01	1130
2026-04-13	IMTX	10.86	0.38	0.00	1210
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-17	IMTX	9.85	-19.3	-	-1.68
2026-03-18	IMTX	9.72	-19.3	-	-1.68
2026-03-19	IMTX	9.70	-19.3	-	-1.74
2026-03-20	IMTX	9.47	-18.7	-	-1.74
2026-03-23	IMTX	9.52	-18.7	-	-1.74
2026-03-24	IMTX	9.19	-18.7	-	-1.74
2026-03-25	IMTX	9.73	-18.7	-	-1.74
2026-03-26	IMTX	9.77	-18.7	-	-1.74
2026-03-27	IMTX	9.37	-18.7	-	-1.74
2026-03-30	IMTX	9.33	-18.7	-	-1.74
2026-03-31	IMTX	9.82	-18.7	-	-1.74
2026-04-01	IMTX	10.01	-18.7	-	-1.74
2026-04-02	IMTX	10.38	-18.7	-	-1.74
2026-04-06	IMTX	10.32	-18.7	-	-1.74
2026-04-07	IMTX	10.26	-18.7	-	-1.74
2026-04-08	IMTX	10.53	-18.7	-	-1.74
2026-04-09	IMTX	10.68	-18.7	-	-1.74
2026-04-10	IMTX	10.43	-18.7	-	-1.74
2026-04-13	IMTX	10.85	-18.7	-	-1.74
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-18	IMTX	0.00	7.99	4.79
2026-03-19	IMTX	0.00	7.99	4.79
2026-03-20	IMTX	0.00	7.99	4.79
2026-03-23	IMTX	0.00	7.99	4.79
2026-03-24	IMTX	0.00	7.99	4.79
2026-03-25	IMTX	0.00	7.99	4.71
2026-03-26	IMTX	0.00	7.99	4.71
2026-03-27	IMTX	0.00	7.99	4.71
2026-03-30	IMTX	0.00	7.59	4.71
2026-03-31	IMTX	0.00	7.59	4.71
2026-04-01	IMTX	0.00	7.59	4.71
2026-04-02	IMTX	0.00	7.59	4.71
2026-04-06	IMTX	0.00	7.59	4.71
2026-04-07	IMTX	0.00	7.59	4.71
2026-04-08	IMTX	0.00	7.59	4.71
2026-04-09	IMTX	0.00	7.59	4.71
2026-04-10	IMTX	0.00	7.59	4.71
2026-04-13	IMTX	0.00	7.54	4.79
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.34

Avg. EPS Est. Current Quarter

-0.44

Avg. EPS Est. Next Quarter

-0.46

Insider Transactions

Institutional Transactions

7.54

Beta

1.33

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

33.4

Max Drawdown 5-Year %

-77.4

Target Price

18.69

P/E

Forward P/E

PEG

P/S

26.99

P/B

2.56

P/Free Cash Flow

EPS

-1.82

Average EPS Est. Cur. Y

-1.74

EPS Next Y. (Est.)

-1.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-411.76

Relative Volume

0.69

Return on Equity vs Sector %

-67.9

Return on Equity vs Industry %

-51.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

◆ IMTX Healthcare

$10.87

📉

Swing / Pullback

Buy the dip on strong trends

WATCH

Trend

20/20

Pullback

6/25

Volume

9/15

Valuation

9/20

TP/AR

4/10

Options

7/10

RSI

62.5

Range 1M

98.9%

Sup Dist

5.4%

🚀

Momentum Growth

Ride accelerating trends

WEAK

Momentum

19/25

Growth

10/30

Estimates

2/20

Inst/Vol

8/15

Options

8/10

EPS Yr

5.3%

EPS NY

0.8%

52W%

81.9%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +71.9% upside

Quality

2/30

Valuation

12/30

Growth

6/25

Stability

8/10

LT Trend

4/5

Upside

+71.9%

Quality

Immatics N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 589

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTX

Latest News

—

Caricamento notizie per IMTX…

stock quote shares IMTX – Immatics N.V Stock Price stock today

news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch IMTX – Immatics N.V yahoo finance google finance

stock history IMTX – Immatics N.V invest stock market

stock prices IMTX premarket after hours

ticker IMTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: IMTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y